🇺🇸 FDA
Pipeline program

RAP-219

RAP-219-BPM-201

Phase 2 small_molecule active

Quick answer

RAP-219 for Bipolar 1 Disorder is a Phase 2 program (small_molecule) at Rapport Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Rapport Therapeutics
Indication
Bipolar 1 Disorder
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials